Drug General Information (ID: DDIQUTB3FS)
Drug Name			Temsirolimus		Drug Info		Antithrombin III human		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Antineoplastics/Mtor Inhibitors				Recombinant Antithrombin

Mechanism of Temsirolimus-Antithrombin III human Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Temsirolimus				Antithrombin III human
Mechanism		Risk of bleeding Antiplatelet/anticoagulant effects				Risk of bleeding Anticoagulant
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Temsirolimus and Antithrombin III human

Recommended Action
Management		Patients receiving anticoagulants should be informed of the increased risk of developing intracerebral bleeding while on temsirolimus.

References
1	Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.